Joshua Zebadiah Willey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joshua Zebadiah Willey has a total of 607 co-authors. Here are the top co-authors by number of shared publications:
- Amelia K. Boehme
Department of Neurology, Columbia University School of Medicine, New York, NY (S.P., A.K.B.).
10 shared publications Mitchell S.V. Elkind
10 shared publicationsRalph L. Sacco
Evelyn McKnight Brain Institute, University of Miami, Miami, Florida, USA
10 shared publications- Shadi Yaghi
Brown University
9 shared publications - Bernadette Boden-Albala
Department of Health, Society, and Behavior, Joe C. Wen School of Population & Public Health, University of California, Irvine, Irvine, CA, USA
8 shared publications Mitchell S. V. Elkind
Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA
8 shared publications
Latest Publications
- 1 April 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (4) , 876-882
Recurrent Cervical Artery Dissection Prevalence and Predictors: A Secondary Analysis of the STOP-CAD Study
BACKGROUND: Patients with cervical artery dissection (CeAD) may experience a recurrent dissection, but its frequency, risk factors, and clinical implications are not well defined. We aimed to determine the risk, associated factors, and clinical impact of recurrent CeAD. METHODS: The STOP-CAD study (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection) was a multicenter international retrospective observational study of patients with CeAD treated between January 2015 and June 2022. Recurrent dissection was defined as a CeAD occurring at least 7 days after the diagnosis of the index event that affects a different artery or a different segment of the same artery. Patients were followed from day 7 up to 2 years. The absolute risk of recurrent CeAD over time was calculated using Kaplan-Meier survival estimates. Multivariable logistic and Cox regression models were used to assess predictors of CeAD recurrence. RESULTS: Of the 4023 patients included in STOP-CAD, 3836 (median age 46 years, 45% women) were eligible for this analysis. During a median (interquartile range) follow-up of 295 (97–720) days, 88 (2.29%) patients had a CeAD recurrence. Median time-to-recurrent CeAD was 53 (interquartile range, 18–157) days. The estimated risk of recurrent CeAD at 2 years was 3.22% (95% CI, 2.59%–4.00%). In multivariable analyses, younger age (adjusted odds ratios, 0.98 [95% CI, 0.96–0.99]), migraine (adjusted odds ratio, 1.88 [95% CI, 1.14–3.07]), and fibromuscular dysplasia (adjusted odds ratio, 2.90 [95% CI, 1.66–5.06]) were associated with CeAD recurrence, while presenting with an ischemic stroke was associated with a lower likelihood of recurrence (adjusted odds ratio, 0.47 [95% CI, 0.29–0.75]). These associations with CeAD recurrence over time were confirmed by Cox regression analyses. Among the 88 patients with recurrent CeAD, only 5 had accompanying ischemic events (3 strokes, 2 transient ischemic attacks). CONCLUSIONS: In this retrospective study, recurrent CeAD was uncommon, approximately half of the events were diagnosed within the first 2 months of the index event, and recurrent events rarely caused new ischemic events. Younger age, migraine, absence of ischemic stroke at presentation, and signs of fibromuscular dysplasia may help identify high-risk patients.
- 1 April 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (4) , 876-882
Recurrent Cervical Artery Dissection Prevalence and Predictors: A Secondary Analysis of the STOP-CAD Study
BACKGROUND: Patients with cervical artery dissection (CeAD) may experience a recurrent dissection, but its frequency, risk factors, and clinical implications are not well defined. We aimed to determine the risk, associated factors, and clinical impact of recurrent CeAD. METHODS: The STOP-CAD study (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection) was a multicenter international retrospective observational study of patients with CeAD treated between January 2015 and June 2022. Recurrent dissection was defined as a CeAD occurring at least 7 days after the diagnosis of the index event that affects a different artery or a different segment of the same artery. Patients were followed from day 7 up to 2 years. The absolute risk of recurrent CeAD over time was calculated using Kaplan-Meier survival estimates. Multivariable logistic and Cox regression models were used to assess predictors of CeAD recurrence. RESULTS: Of the 4023 patients included in STOP-CAD, 3836 (median age 46 years, 45% women) were eligible for this analysis. During a median (interquartile range) follow-up of 295 (97–720) days, 88 (2.29%) patients had a CeAD recurrence. Median time-to-recurrent CeAD was 53 (interquartile range, 18–157) days. The estimated risk of recurrent CeAD at 2 years was 3.22% (95% CI, 2.59%–4.00%). In multivariable analyses, younger age (adjusted odds ratios, 0.98 [95% CI, 0.96–0.99]), migraine (adjusted odds ratio, 1.88 [95% CI, 1.14–3.07]), and fibromuscular dysplasia (adjusted odds ratio, 2.90 [95% CI, 1.66–5.06]) were associated with CeAD recurrence, while presenting with an ischemic stroke was associated with a lower likelihood of recurrence (adjusted odds ratio, 0.47 [95% CI, 0.29–0.75]). These associations with CeAD recurrence over time were confirmed by Cox regression analyses. Among the 88 patients with recurrent CeAD, only 5 had accompanying ischemic events (3 strokes, 2 transient ischemic attacks). CONCLUSIONS: In this retrospective study, recurrent CeAD was uncommon, approximately half of the events were diagnosed within the first 2 months of the index event, and recurrent events rarely caused new ischemic events. Younger age, migraine, absence of ischemic stroke at presentation, and signs of fibromuscular dysplasia may help identify high-risk patients.
- 1 March 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (1)
Mediterranean Diet and the Risk of Stroke Subtypes in Women
Mediterranean diet (MeDi) has been linked to lower incidence of cardiovascular and neurodegenerative diseases, and overall mortality, in several prospective studies. There is limited data, however, regarding the relationship between MeDi and stroke subtypes. We hypothesized that MeDi would be associated with lower total, ischemic, and hemorrhagic stroke incidence. The California Teachers Study is a prospective cohort study that comprises 133,477 women who were educators and administrators enrolled in 1995-1996 and followed since. We identified incident strokes using linked California state hospitalization data and national death records from 1996-2020. The MeDi adherence score (range 0-9, higher score indicating better adherence) was calculated based on participants' response to the Block food frequency questionnaire at study baseline. Multivariable Cox proportional hazard models adjusted for socio-demographic, lifestyle and vascular risk variables were constructed to assess the association (hazard ratios and 95% confidence intervals, HR 95% CI) between MeDi score and risk of stroke and its subtypes. 105,614 participants were eligible and included in the final analytic cohort (mean age 52.5 ± 13.8 years). Over the follow-up period (average follow-up time was 20.5 years), there were 4,083 incident stroke events (3,358 ischemic; 725 hemorrhagic). In fully-adjusted models for all stroke, ischemic and hemorrhagic subtypes, there was a lower risk of stroke among those with MeDi scores of 6-9 compared to those with scores of 0-2 (all stroke HR 0.82, 95% CI 0.74-0.92; ischemic HR 0.84, 95% CI 0.75 - 0.95; hemorrhagic HR 0.75, 95% CI 0.58-0.97). Adherence to the MeDi is associated with lower risk of total, ischemic, and hemorrhagic stroke incidence among women. Potential study limitations include recall bias, misclassification bias, and residual confounding, which would bias our results to the null.
- 1 March 2026
- Published by Wolters Kluwer Health in Neurology Open Access
- Vol. 2 (1)
Mediterranean Diet and the Risk of Stroke Subtypes in Women
Mediterranean diet (MeDi) has been linked to lower incidence of cardiovascular and neurodegenerative diseases, and overall mortality, in several prospective studies. There is limited data, however, regarding the relationship between MeDi and stroke subtypes. We hypothesized that MeDi would be associated with lower total, ischemic, and hemorrhagic stroke incidence. The California Teachers Study is a prospective cohort study that comprises 133,477 women who were educators and administrators enrolled in 1995-1996 and followed since. We identified incident strokes using linked California state hospitalization data and national death records from 1996-2020. The MeDi adherence score (range 0-9, higher score indicating better adherence) was calculated based on participants' response to the Block food frequency questionnaire at study baseline. Multivariable Cox proportional hazard models adjusted for socio-demographic, lifestyle and vascular risk variables were constructed to assess the association (hazard ratios and 95% confidence intervals, HR 95% CI) between MeDi score and risk of stroke and its subtypes. 105,614 participants were eligible and included in the final analytic cohort (mean age 52.5 ± 13.8 years). Over the follow-up period (average follow-up time was 20.5 years), there were 4,083 incident stroke events (3,358 ischemic; 725 hemorrhagic). In fully-adjusted models for all stroke, ischemic and hemorrhagic subtypes, there was a lower risk of stroke among those with MeDi scores of 6-9 compared to those with scores of 0-2 (all stroke HR 0.82, 95% CI 0.74-0.92; ischemic HR 0.84, 95% CI 0.75 - 0.95; hemorrhagic HR 0.75, 95% CI 0.58-0.97). Adherence to the MeDi is associated with lower risk of total, ischemic, and hemorrhagic stroke incidence among women. Potential study limitations include recall bias, misclassification bias, and residual confounding, which would bias our results to the null.
- 1 March 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (3) , 633-640
Potential Missed Opportunities to Administer Intravenous Thrombolysis to Patients With Acute Ischemic Stroke
BACKGROUND: Recent years have seen improvements in stroke-care pathways, including mobile stroke units (MSUs), and this may have affected the rate, predictors, and outcomes of patients with acute ischemic stroke who qualify for but do not receive treatment with intravenous thrombolysis (IVT). METHODS: This was a secondary observational cohort analysis of the prospective, multicenter BEST-MSU trial (Benefits of Stroke Treatment Delivered by a Mobile Stroke Unit Compared With Standard Management by Emergency Medical Services), conducted in 7 US cities from 2014 to 2020, comparing MSU management versus standard emergency department management for patients with suspected acute ischemic stroke. The analytical cohort comprised enrolled patients with confirmed acute ischemic stroke and no guideline contraindications to IVT. The outcome was a potential missed IVT opportunity, defined as patients not treated with IVT despite lacking contraindications. We used multivariable logistic regression to evaluate whether demographics, prestroke modified Rankin Scale, study site, comorbidities, National Institutes of Health Stroke Scale, blood pressure, international normalized ratio, glucose, antithrombotic use, and thrombectomy were associated with this outcome. RESULTS: Of 1515 enrolled patients, 927 met criteria for this analysis. Fifty-one participants (5.5%) had a potential missed IVT opportunity, including 4 of 555 (0.7%) in the MSU group versus 47 of 372 (12.6%) in the emergency department group (odds ratio, 0.05 [95% CI, 0.02–0.12]). In multivariable analysis, omitting study group, lower National Institutes of Health Stroke Scale (odds ratio, 0.95 [95% CI, 0.90–0.99]) and longer last known well-to-door time (odds ratio per 10 minutes, 1.08 [95% CI, 1.03–1.13]) were independently associated with a potential missed IVT opportunity. The leading reasons documented for withholding IVT were resolving symptoms (43%), time window concerns (18%), and minor deficits (10%). Among participants with a potential missed IVT opportunity and a recorded 3-month modified Rankin Scale (n=49), 19 (39%) had a score of 3 to 6. CONCLUSIONS: In the BEST-MSU trial, potential missed IVT opportunities occurred in 1-in-8 patients in the emergency department, and rarely on the MSU. Although often due to early improvement or minor deficits, more than one-third of these patients had poor functional status at 3 months. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02190500.
- 1 March 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (3) , 633-640
Potential Missed Opportunities to Administer Intravenous Thrombolysis to Patients With Acute Ischemic Stroke
BACKGROUND: Recent years have seen improvements in stroke-care pathways, including mobile stroke units (MSUs), and this may have affected the rate, predictors, and outcomes of patients with acute ischemic stroke who qualify for but do not receive treatment with intravenous thrombolysis (IVT). METHODS: This was a secondary observational cohort analysis of the prospective, multicenter BEST-MSU trial (Benefits of Stroke Treatment Delivered by a Mobile Stroke Unit Compared With Standard Management by Emergency Medical Services), conducted in 7 US cities from 2014 to 2020, comparing MSU management versus standard emergency department management for patients with suspected acute ischemic stroke. The analytical cohort comprised enrolled patients with confirmed acute ischemic stroke and no guideline contraindications to IVT. The outcome was a potential missed IVT opportunity, defined as patients not treated with IVT despite lacking contraindications. We used multivariable logistic regression to evaluate whether demographics, prestroke modified Rankin Scale, study site, comorbidities, National Institutes of Health Stroke Scale, blood pressure, international normalized ratio, glucose, antithrombotic use, and thrombectomy were associated with this outcome. RESULTS: Of 1515 enrolled patients, 927 met criteria for this analysis. Fifty-one participants (5.5%) had a potential missed IVT opportunity, including 4 of 555 (0.7%) in the MSU group versus 47 of 372 (12.6%) in the emergency department group (odds ratio, 0.05 [95% CI, 0.02–0.12]). In multivariable analysis, omitting study group, lower National Institutes of Health Stroke Scale (odds ratio, 0.95 [95% CI, 0.90–0.99]) and longer last known well-to-door time (odds ratio per 10 minutes, 1.08 [95% CI, 1.03–1.13]) were independently associated with a potential missed IVT opportunity. The leading reasons documented for withholding IVT were resolving symptoms (43%), time window concerns (18%), and minor deficits (10%). Among participants with a potential missed IVT opportunity and a recorded 3-month modified Rankin Scale (n=49), 19 (39%) had a score of 3 to 6. CONCLUSIONS: In the BEST-MSU trial, potential missed IVT opportunities occurred in 1-in-8 patients in the emergency department, and rarely on the MSU. Although often due to early improvement or minor deficits, more than one-third of these patients had poor functional status at 3 months. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02190500.
- 20 December 2025
- Published by SAGE Publications in The Neurohospitalist
- Vol. 16 (3) , 265-271
Short-Term Prognosis After Endovascular Thrombectomy in Patients With Brain Tumors: A Nationwide Analysis
Background and Purpose: The utilization and outcomes of endovascular thrombectomy (EVT) for acute ischemic stroke (AIS) in the presence of brain tumors has not been studied. Using the National Inpatient Sample (NIS), we performed a retrospective analysis of the rate of utilization of EVT in patients with AIS and brain tumors and their odds of in-hospital mortality and home discharge. Methods: All adult (≥18 years) AIS patients with brain tumors of malignant, benign, or undetermined subtypes, and EVT use were identified in the NIS (2016-2019). Outcomes were odds of home discharge and in-hospital mortality, adjusted for age, sex, race, income, insurance, hospital size, intravenous tissue plasminogen activator (IV-tPA) use, and clinical severity of hospital admission. Results: Of 533,351 AIS patients, 7070 (1.3%) had brain tumors. Sixty-two percent were malignant, 33% benign, and 5.2% undetermined. Patients with brain tumors less frequently received IV-tPA (3.4% vs 10.3%) and EVT (1.9% vs 3.6%) ( P < 0.001). Home discharge after EVT was similar in patients with vs without brain tumors, for all tumor subtypes (28.0% vs 28.4%, P = 0.933). In-hospital mortality was higher with brain tumors (22.6% vs 13.0%, P < 0.001), but largely driven by malignant subtype. In adjusted analysis, only patients with malignant tumors experienced greater in-hospital death after EVT (aOR: 2.78, 95% CI: 1.61-4.80). Conclusions: Patients with malignant brain tumors may have higher in-hospital mortality after EVT but similar rate of home discharge. These results are limited by lack of information on confounders such as brain tumor characteristics and causes of mortality in the NIS.
- 20 December 2025
- Published by SAGE Publications in The Neurohospitalist
- Vol. 16 (3) , 265-271
Short-Term Prognosis After Endovascular Thrombectomy in Patients With Brain Tumors: A Nationwide Analysis
Background and Purpose: The utilization and outcomes of endovascular thrombectomy (EVT) for acute ischemic stroke (AIS) in the presence of brain tumors has not been studied. Using the National Inpatient Sample (NIS), we performed a retrospective analysis of the rate of utilization of EVT in patients with AIS and brain tumors and their odds of in-hospital mortality and home discharge. Methods: All adult (≥18 years) AIS patients with brain tumors of malignant, benign, or undetermined subtypes, and EVT use were identified in the NIS (2016-2019). Outcomes were odds of home discharge and in-hospital mortality, adjusted for age, sex, race, income, insurance, hospital size, intravenous tissue plasminogen activator (IV-tPA) use, and clinical severity of hospital admission. Results: Of 533,351 AIS patients, 7070 (1.3%) had brain tumors. Sixty-two percent were malignant, 33% benign, and 5.2% undetermined. Patients with brain tumors less frequently received IV-tPA (3.4% vs 10.3%) and EVT (1.9% vs 3.6%) ( P < 0.001). Home discharge after EVT was similar in patients with vs without brain tumors, for all tumor subtypes (28.0% vs 28.4%, P = 0.933). In-hospital mortality was higher with brain tumors (22.6% vs 13.0%, P < 0.001), but largely driven by malignant subtype. In adjusted analysis, only patients with malignant tumors experienced greater in-hospital death after EVT (aOR: 2.78, 95% CI: 1.61-4.80). Conclusions: Patients with malignant brain tumors may have higher in-hospital mortality after EVT but similar rate of home discharge. These results are limited by lack of information on confounders such as brain tumor characteristics and causes of mortality in the NIS.
- 1 June 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (6) , 1413-1421
Factors Associated With Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection
BACKGROUND: Patients presenting with cervical artery dissection (CAD) are at risk for subsequent ischemic events. We aimed to identify characteristics that are associated with increased risk of ischemic stroke after initial presentation of CAD and to evaluate the differential impact of anticoagulant versus antiplatelet therapy in these high-risk individuals. METHODS: This was a preplanned secondary analysis of the STOP-CAD study (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection), a multicenter international retrospective observational study (63 sites from 16 countries in North America, South America, Europe, Asia, and Africa) that included patients with CAD predominantly between January 2015 and June 2022. The primary outcome was subsequent ischemic stroke by day 180 after diagnosis. Clinical and imaging variables were compared between those with versus without subsequent ischemic stroke. Significant factors associated with subsequent stroke risk were identified using stepwise Cox regression. Associations between subsequent ischemic stroke risk and antithrombotic therapy type (anticoagulation versus antiplatelets) among patients with identified risk factors were explored using adjusted Cox regression. RESULTS: In all, 4023 patients (mean age was 47.4 years; 44.5% were women) were included. By day 180, subsequent ischemic stroke occurred in 5.3% of the cohort. In adjusted Cox regression, factors associated with increased risk of subsequent ischemic stroke were prior history of ischemic stroke (adjusted hazard ratio [aHR], 7.31 [95% CI, 1.61–33.13]; P =0.010), presentation within 7 days from first symptoms (aHR, 3.04 [95% CI, 1.04–8.91]; P =0.043), infarct on baseline imaging (aHR, 9.85 [95% CI, 3.65–26.58]; P P =0.043). Only patients with occlusive dissection demonstrated a reduced risk of subsequent ischemic stroke when treated with anticoagulation versus antiplatelets (aHR, 0.36 [95% CI, 0.16–0.80]; P =0.01). CONCLUSIONS: In this post hoc analysis of the STOP-CAD study, several factors associated with subsequent ischemic stroke were identified among patients with CAD. Furthermore, we identified a potential benefit of anticoagulation in patients with CAD with occlusive dissection. These findings require validation by meta-analyses of prior studies to formulate optimal treatment strategies for specific high-risk CAD subgroups.
- 1 June 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (6) , 1413-1421
Factors Associated With Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection
BACKGROUND: Patients presenting with cervical artery dissection (CAD) are at risk for subsequent ischemic events. We aimed to identify characteristics that are associated with increased risk of ischemic stroke after initial presentation of CAD and to evaluate the differential impact of anticoagulant versus antiplatelet therapy in these high-risk individuals. METHODS: This was a preplanned secondary analysis of the STOP-CAD study (Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection), a multicenter international retrospective observational study (63 sites from 16 countries in North America, South America, Europe, Asia, and Africa) that included patients with CAD predominantly between January 2015 and June 2022. The primary outcome was subsequent ischemic stroke by day 180 after diagnosis. Clinical and imaging variables were compared between those with versus without subsequent ischemic stroke. Significant factors associated with subsequent stroke risk were identified using stepwise Cox regression. Associations between subsequent ischemic stroke risk and antithrombotic therapy type (anticoagulation versus antiplatelets) among patients with identified risk factors were explored using adjusted Cox regression. RESULTS: In all, 4023 patients (mean age was 47.4 years; 44.5% were women) were included. By day 180, subsequent ischemic stroke occurred in 5.3% of the cohort. In adjusted Cox regression, factors associated with increased risk of subsequent ischemic stroke were prior history of ischemic stroke (adjusted hazard ratio [aHR], 7.31 [95% CI, 1.61–33.13]; P =0.010), presentation within 7 days from first symptoms (aHR, 3.04 [95% CI, 1.04–8.91]; P =0.043), infarct on baseline imaging (aHR, 9.85 [95% CI, 3.65–26.58]; P P =0.043). Only patients with occlusive dissection demonstrated a reduced risk of subsequent ischemic stroke when treated with anticoagulation versus antiplatelets (aHR, 0.36 [95% CI, 0.16–0.80]; P =0.01). CONCLUSIONS: In this post hoc analysis of the STOP-CAD study, several factors associated with subsequent ischemic stroke were identified among patients with CAD. Furthermore, we identified a potential benefit of anticoagulation in patients with CAD with occlusive dissection. These findings require validation by meta-analyses of prior studies to formulate optimal treatment strategies for specific high-risk CAD subgroups.
- Open Access
Artificial Intelligence for Short-Term Modified Rankin Score Prediction after Acute Stroke Symptoms Using Wrist-worn Triaxial Accelerometry Data
Background Functional outcomes after stroke are commonly assessed via modified Rankin Scale (mRS). However, mRS is subject to patient and assessor biases and is impractical to collect in many cases, limiting its impact on post-stroke care. Artificial intelligence (AI) applied to wrist-worn triaxial accelerometry (WWTA) device data can objectively characterize post-stroke functional status and related changes. Methods We used patient data from REACH Stroke-Sleep, a study investigating WWTA-derived measures of sleep, physical activity, and recurrent stroke risk among patients with acute stroke symptoms. We determined moving accelerometry averages and vector sums over four time windows (minute, hour, day, week). We trained a tree-based (random forest; RF) and deep learning (LSTM) model to predict individual 6-month mRS scores and differences between 1- and 6-month mRS scores. We used 5-fold cross validation, modeled each outcome as binary exact-match between actual-predicted values, and determined area under the receiver-operating curve (AUROC), sensitivity, precision, negative predictive value, and F1 scores for both models. For mRS score differences, we determined mean absolute error (MAE) and standard deviation (SD). Results We identified 362 patients in REACH Stroke-Sleep, of whom 302 (83.4%) had a 1-month mRS score, 251 (69.3%) had a 6-month mRS score, and 191 (52.8%) had both. Patients wore devices for median 41.0 (IQR 34.4-44.0) days. For all outcomes, RF models (6-month AUROC 0.81, 95%CI 0.74- 0.89; 1-6 month mRS AUROC 0.82, 95%CI 0.76-0.90) outperformed LSTM models (6-month AUROC 0.63, 95%CI 0.55–0.71; 1-6 month mRS AUROC 0.53, 95%CI 0.45-0.61). RF models (MAE 0.37, SD 0.12) outperformed LSTM (MAE 0.87, SD 0.48) for predicting 1-6 month mRS difference, modeled as a non-binarized outcome. Conclusions We found that AI predicted short-term mRS and mRS changes after acute stroke symptoms from WWTA data with moderate performance. Future studies are warranted to investigate whether multimodal data can improve performance with the goal of developing objective, automatable functional status assessments.
Open AccessArtificial Intelligence for Short-Term Modified Rankin Score Prediction after Acute Stroke Symptoms Using Wrist-worn Triaxial Accelerometry Data
Background Functional outcomes after stroke are commonly assessed via modified Rankin Scale (mRS). However, mRS is subject to patient and assessor biases and is impractical to collect in many cases, limiting its impact on post-stroke care. Artificial intelligence (AI) applied to wrist-worn triaxial accelerometry (WWTA) device data can objectively characterize post-stroke functional status and related changes. Methods We used patient data from REACH Stroke-Sleep, a study investigating WWTA-derived measures of sleep, physical activity, and recurrent stroke risk among patients with acute stroke symptoms. We determined moving accelerometry averages and vector sums over four time windows (minute, hour, day, week). We trained a tree-based (random forest; RF) and deep learning (LSTM) model to predict individual 6-month mRS scores and differences between 1- and 6-month mRS scores. We used 5-fold cross validation, modeled each outcome as binary exact-match between actual-predicted values, and determined area under the receiver-operating curve (AUROC), sensitivity, precision, negative predictive value, and F1 scores for both models. For mRS score differences, we determined mean absolute error (MAE) and standard deviation (SD). Results We identified 362 patients in REACH Stroke-Sleep, of whom 302 (83.4%) had a 1-month mRS score, 251 (69.3%) had a 6-month mRS score, and 191 (52.8%) had both. Patients wore devices for median 41.0 (IQR 34.4-44.0) days. For all outcomes, RF models (6-month AUROC 0.81, 95%CI 0.74- 0.89; 1-6 month mRS AUROC 0.82, 95%CI 0.76-0.90) outperformed LSTM models (6-month AUROC 0.63, 95%CI 0.55–0.71; 1-6 month mRS AUROC 0.53, 95%CI 0.45-0.61). RF models (MAE 0.37, SD 0.12) outperformed LSTM (MAE 0.87, SD 0.48) for predicting 1-6 month mRS difference, modeled as a non-binarized outcome. Conclusions We found that AI predicted short-term mRS and mRS changes after acute stroke symptoms from WWTA data with moderate performance. Future studies are warranted to investigate whether multimodal data can improve performance with the goal of developing objective, automatable functional status assessments.
- 8 October 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (7) , e209843
Intravenous Thrombolysis in Patients With Cervical Artery Dissection
Cervical artery dissection (CeAD) accounts for 25% of ischemic strokes in young adults. This study evaluated the benefits and harms of intravenous thrombolysis (IVT) in patients presenting with spontaneous CeAD and acute ischemic stroke symptoms. This analysis used data from the retrospective STOP-CAD study and included patients with spontaneous CeAD who presented within 1 day of acute ischemic stroke symptoms. Patients were dichotomized into those who received IVT and those managed without IVT. We assessed the association between IVT and 90-day functional independence (modified Rankin Scale scores 0-2) and the incidence of symptomatic intracranial hemorrhage (ICH, defined as ICH causing new or worsening neurologic symptoms within 72 hours after CeAD diagnosis). This study included 1,653 patients from the original STOP-CAD cohort of 4,023. The median age was 49 years, and 35.1% were women; 512 (31.0%) received IVT. IVT was associated with 90-day functional independence (adjusted odds ratio [aOR] = 1.67, 95% CI 1.23-2.28, p = 0.001), but not with symptomatic ICH (aOR = 1.52, 95% CI 0.79-2.92, p = 0.215). In patients with spontaneous CeAD and suspected ischemic stroke, IVT improved functional outcomes, without increasing symptomatic ICH risk. These findings support current guideline recommendations to consider thrombolysis for otherwise eligible patients with CeAD. This study provides Class III evidence that IVT significantly increases the probability of 90-day functional independence in patients with CeAD.
- 8 October 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (7) , e209843
Intravenous Thrombolysis in Patients With Cervical Artery Dissection
Cervical artery dissection (CeAD) accounts for 25% of ischemic strokes in young adults. This study evaluated the benefits and harms of intravenous thrombolysis (IVT) in patients presenting with spontaneous CeAD and acute ischemic stroke symptoms. This analysis used data from the retrospective STOP-CAD study and included patients with spontaneous CeAD who presented within 1 day of acute ischemic stroke symptoms. Patients were dichotomized into those who received IVT and those managed without IVT. We assessed the association between IVT and 90-day functional independence (modified Rankin Scale scores 0-2) and the incidence of symptomatic intracranial hemorrhage (ICH, defined as ICH causing new or worsening neurologic symptoms within 72 hours after CeAD diagnosis). This study included 1,653 patients from the original STOP-CAD cohort of 4,023. The median age was 49 years, and 35.1% were women; 512 (31.0%) received IVT. IVT was associated with 90-day functional independence (adjusted odds ratio [aOR] = 1.67, 95% CI 1.23-2.28, p = 0.001), but not with symptomatic ICH (aOR = 1.52, 95% CI 0.79-2.92, p = 0.215). In patients with spontaneous CeAD and suspected ischemic stroke, IVT improved functional outcomes, without increasing symptomatic ICH risk. These findings support current guideline recommendations to consider thrombolysis for otherwise eligible patients with CeAD. This study provides Class III evidence that IVT significantly increases the probability of 90-day functional independence in patients with CeAD.
- Open Access
Predictors of Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection
Objective Patients with cervical artery dissection (CAD) are at increased ischemic stroke risk. We aimed to identify characteristics that are associated with increased risk of ischemic stroke following initial presentation of CAD and to evaluate the differential impact of anticoagulant versus antiplatelet therapy in these high-risk individuals. Methods This was a secondary analysis of the Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection (STOP-CAD) study, a multicenter retrospective observational study. The primary outcome was subsequent ischemic stroke by day 180 after diagnosis. Patient characteristics were compared between those with vs. without subsequent ischemic stroke. Significant predictors were identified using stepwise Cox regression. Associations between subsequent ischemic stroke risk and antithrombotic therapy type in high-risk patients were explored using adjusted Cox regression. Results 4,023 patients (mean age 47.4 years; 44.5% were women) were included. By day 180, 5.3% experienced a subsequent ischemic stroke. In adjusted Cox regression, factors associated with increased subsequent ischemic stroke risk were prior ischemic stroke (aHR 7.31, 95% CI 1.61-33.13, p=0.010), presentation within seven days from symptoms, (aHR 3.04, 95% CI 1.04-8.91, p=0.043), infarct on imaging (aHR 9.85, 95% CI 3.65-26.58, pInterpretation This study identified several predictors of subsequent ischemic stroke among patients with CAD but only patients with occlusive dissection demonstrated a benefit from anticoagulation. These findings require validation by meta-analyses of prior studies.
Open AccessPredictors of Stroke Recurrence After Initial Diagnosis of Cervical Artery Dissection
Objective Patients with cervical artery dissection (CAD) are at increased ischemic stroke risk. We aimed to identify characteristics that are associated with increased risk of ischemic stroke following initial presentation of CAD and to evaluate the differential impact of anticoagulant versus antiplatelet therapy in these high-risk individuals. Methods This was a secondary analysis of the Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection (STOP-CAD) study, a multicenter retrospective observational study. The primary outcome was subsequent ischemic stroke by day 180 after diagnosis. Patient characteristics were compared between those with vs. without subsequent ischemic stroke. Significant predictors were identified using stepwise Cox regression. Associations between subsequent ischemic stroke risk and antithrombotic therapy type in high-risk patients were explored using adjusted Cox regression. Results 4,023 patients (mean age 47.4 years; 44.5% were women) were included. By day 180, 5.3% experienced a subsequent ischemic stroke. In adjusted Cox regression, factors associated with increased subsequent ischemic stroke risk were prior ischemic stroke (aHR 7.31, 95% CI 1.61-33.13, p=0.010), presentation within seven days from symptoms, (aHR 3.04, 95% CI 1.04-8.91, p=0.043), infarct on imaging (aHR 9.85, 95% CI 3.65-26.58, pInterpretation This study identified several predictors of subsequent ischemic stroke among patients with CAD but only patients with occlusive dissection demonstrated a benefit from anticoagulation. These findings require validation by meta-analyses of prior studies.
- 3 November 2023
- Published by Springer Nature in Current Cardiology Reports
- Vol. 25 (12) , 1665-1675
Stroke and Mechanical Circulatory Support in Adults
Purpose of the Review Short-term and durable mechanical circulatory support (MCS) devices represent life-saving interventions for patients with cardiogenic shock and end-stage heart failure. This review will cover the epidemiology, risk factors, and treatment of stroke in this patient population. Recent Findings Short-term devices such as intra-aortic balloon pump, Impella, TandemHeart, and Venoatrial Extracorporal Membrane Oxygenation, as well as durable continuous-flow left ventricular assist devices (LVADs), improve cardiac output and blood flow to the vital organs. However, MCS use is associated with high rates of complications, including ischemic and hemorrhagic strokes which carry a high risk for death and disability. Improvements in MCS technology have reduced but not eliminated the risk of stroke. Mitigation strategies focus on careful management of anti-thrombotic therapies. While data on therapeutic options for stroke are limited, several case series reported favorable outcomes with thrombectomy for ischemic stroke patients with large vessel occlusions, as well as with reversal of anticoagulation for those with hemorrhagic stroke. Summary Stroke in patients treated with MCS is associated with high morbidity and mortality. Preventive strategies are targeted based on the specific form of MCS. Improvements in the design of the newest generation device have reduced the risk of ischemic stroke, though hemorrhagic stroke remains a serious complication.
- 3 November 2023
- Published by Springer Nature in Current Cardiology Reports
- Vol. 25 (12) , 1665-1675
Stroke and Mechanical Circulatory Support in Adults
Purpose of the Review Short-term and durable mechanical circulatory support (MCS) devices represent life-saving interventions for patients with cardiogenic shock and end-stage heart failure. This review will cover the epidemiology, risk factors, and treatment of stroke in this patient population. Recent Findings Short-term devices such as intra-aortic balloon pump, Impella, TandemHeart, and Venoatrial Extracorporal Membrane Oxygenation, as well as durable continuous-flow left ventricular assist devices (LVADs), improve cardiac output and blood flow to the vital organs. However, MCS use is associated with high rates of complications, including ischemic and hemorrhagic strokes which carry a high risk for death and disability. Improvements in MCS technology have reduced but not eliminated the risk of stroke. Mitigation strategies focus on careful management of anti-thrombotic therapies. While data on therapeutic options for stroke are limited, several case series reported favorable outcomes with thrombectomy for ischemic stroke patients with large vessel occlusions, as well as with reversal of anticoagulation for those with hemorrhagic stroke. Summary Stroke in patients treated with MCS is associated with high morbidity and mortality. Preventive strategies are targeted based on the specific form of MCS. Improvements in the design of the newest generation device have reduced the risk of ischemic stroke, though hemorrhagic stroke remains a serious complication.
- 20 October 2023
- Published by Wiley in Annals of Neurology
- Vol. 95 (2) , 347-361
Strokes Averted by Intravenous Thrombolysis: A Secondary Analysis of a Prospective, Multicenter, Controlled Trial of Mobile Stroke Units
Objective: This study was undertaken to examine averted stroke in optimized stroke systems.Methods: This secondary analysis of a multicenter trial from 2014 to 2020 compared patients treated by mobile stroke unit (MSU) versus standard management. The analytical cohort consisted of participants with suspected stroke treated with intravenous thrombolysis. The main outcome was a tissue‐defined averted stroke, defined as a final diagnosis of stroke with resolution of presenting symptoms/signs by 24 hours attributed to thrombolysis and no acute infarction/hemorrhage on imaging. An additional outcome was stroke with early symptom resolution, defined as a final diagnosis of stroke with resolution of presenting symptoms/signs by 24 hours attributed to thrombolysis.Results: Among 1,009 patients with a median last known well to thrombolysis time of 87 minutes, 159 (16%) had tissue‐defined averted stroke and 276 (27%) had stroke with early symptom resolution. Compared with standard management, MSU care was associated with more tissue‐defined averted stroke (18% vs 11%, adjusted odds ratio [aOR] = 1.82, 95% confidence interval [CI] = 1.13–2.98) and stroke with early symptom resolution (31% vs 21%, aOR = 1.74, 95% CI = 1.12–2.61). The relationships between thrombolysis treatment time and averted/early recovered stroke appeared nonlinear. Most models indicated increased odds for stroke with early symptom resolution but not tissue‐defined averted stroke with earlier treatment. Additionally, younger age, female gender, hyperlipidemia, lower National Institutes of Health Stroke Scale, lower blood pressure, and no large vessel occlusion were associated with both tissue‐defined averted stroke and stroke with early symptom resolution.Interpretation: In optimized stroke systems, 1 in 4 patients treated with thrombolysis recovered within 24 hours and 1 in 6 had no demonstrable brain injury on imaging. ANN NEUROL 2024;95:347–361
- 20 October 2023
- Published by Wiley in Annals of Neurology
- Vol. 95 (2) , 347-361
Strokes Averted by Intravenous Thrombolysis: A Secondary Analysis of a Prospective, Multicenter, Controlled Trial of Mobile Stroke Units
Objective: This study was undertaken to examine averted stroke in optimized stroke systems.Methods: This secondary analysis of a multicenter trial from 2014 to 2020 compared patients treated by mobile stroke unit (MSU) versus standard management. The analytical cohort consisted of participants with suspected stroke treated with intravenous thrombolysis. The main outcome was a tissue‐defined averted stroke, defined as a final diagnosis of stroke with resolution of presenting symptoms/signs by 24 hours attributed to thrombolysis and no acute infarction/hemorrhage on imaging. An additional outcome was stroke with early symptom resolution, defined as a final diagnosis of stroke with resolution of presenting symptoms/signs by 24 hours attributed to thrombolysis.Results: Among 1,009 patients with a median last known well to thrombolysis time of 87 minutes, 159 (16%) had tissue‐defined averted stroke and 276 (27%) had stroke with early symptom resolution. Compared with standard management, MSU care was associated with more tissue‐defined averted stroke (18% vs 11%, adjusted odds ratio [aOR] = 1.82, 95% confidence interval [CI] = 1.13–2.98) and stroke with early symptom resolution (31% vs 21%, aOR = 1.74, 95% CI = 1.12–2.61). The relationships between thrombolysis treatment time and averted/early recovered stroke appeared nonlinear. Most models indicated increased odds for stroke with early symptom resolution but not tissue‐defined averted stroke with earlier treatment. Additionally, younger age, female gender, hyperlipidemia, lower National Institutes of Health Stroke Scale, lower blood pressure, and no large vessel occlusion were associated with both tissue‐defined averted stroke and stroke with early symptom resolution.Interpretation: In optimized stroke systems, 1 in 4 patients treated with thrombolysis recovered within 24 hours and 1 in 6 had no demonstrable brain injury on imaging. ANN NEUROL 2024;95:347–361